Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author of the study, have made a discovery that opens a new avenue for potential cancer therapies. The two scientists published a study in Molecular Cell showing that an enzyme complex called HTC (hydride transfer complex) can inhibit cell aging.
When cells age, a state called “cellular senescence” occurs and cells stop dividing. HTC, composed of three enzymes, may be a potential target for stopping the growth of cancer cells in certain types of cancer, including prostate cancer.
Anne-Marie Mes-Masson’s team is one of the winning teams of the LeadAction competition | Breast Cancer
14 July 2020
The team of Anne-Marie Mes-Masson, researcher at the Montreal Cancer Institute, is one of the winning teams of the LeadAction […]
Dr. David Roberge: Appointment to the Canadian Association of Radiation Oncology
17 January 2022
The Institute would like to acknowledge the appointment of Dr. David Roberge as President-Elect of the Canadian Association of Radiation […]